Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties
about
Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrinsInteraction of endostatin with integrins implicated in angiogenesisPhysiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrinIdentification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activityAntiangiogenic gene therapy of cancer: recent developmentsMatricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor CellsMammalian collagen IVIdentification of a novel integrin alpha 6 beta 1 binding site in the angiogenic inducer CCN1 (CYR61)How matrix metalloproteinases regulate cell behaviorOpticin exerts its anti-angiogenic activity by regulating extracellular matrix adhesivenessTetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine.Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis.Loss of alpha3(IV) collagen expression associated with corneal keratocyte activation.Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets.The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma.Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent alphavbeta3 integrin conformersPharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis.Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis.Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrinMatrix metalloproteinase control of capillary morphogenesis.Angiogenesis and chronic kidney disease.Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect.Basement membranes: cell scaffoldings and signaling platforms.Tiny dancers: the integrin-growth factor nexus in angiogenic signaling.A reevaluation of integrins as regulators of angiogenesis.New functional roles for non-collagenous domains of basement membrane collagensCollagen type IV at the fetal-maternal interface.Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosisImpact of ischemia-reperfusion on extracellular matrix processing and structure of the basement membrane of the heartThe diverse roles of integrins and their ligands in angiogenesis.Endothelial FAK as a therapeutic target in disease.Apoptotic cues from the extracellular matrix: regulators of angiogenesis.Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular MatrixExploration of peptide T7 and its derivative as integrin αvβ3-targeted imaging agents.AntiAngioPred: A Server for Prediction of Anti-Angiogenic PeptidesTumstatin 185-191 increases the sensitivity of non-small cell lung carcinoma cells to cisplatin by blocking proliferation, promoting apoptosis and inhibiting Akt activation.Tumstatin induces apoptosis mediated by Fas signaling pathway in oral squamous cell carcinoma SCC-VII cells.Regulation of matrix biology by matrix metalloproteinases.Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
P2860
Q24299560-DCD507C7-C0E4-41ED-B187-AB5AA3775226Q24545535-8966601C-DC62-4828-B452-CF70920638D9Q24641850-E48F152B-38B5-4B11-BFAE-5AD4DC077322Q24652387-78C27F9B-BB71-489D-B4A5-B67B8653EFCFQ24803786-43882F07-0B43-4588-8C29-4B264632EDFFQ26766481-1B1F1894-48C1-4F98-B17A-F2A39D2ACE07Q28265884-9F949543-B7C3-4ED9-A2FB-EAEE0854956AQ28513880-62F25D7D-176E-4782-B66F-20C1B2C72685Q29620360-6EDF0674-6271-4ED3-BCFF-A790C2DDC627Q30524624-1D751739-7D93-46D4-AFA5-1B3D6E8EE2F9Q31058993-0ADE78F2-5B5D-4F5A-BE38-56CB17FA6DBBQ33237435-08706005-A366-4D7E-B3BF-6CECA83C16DEQ33270259-278D14A5-307E-413F-B80B-6B7FACDA0229Q33414123-24532EE9-9B33-47C3-A100-86A5EB997611Q33554948-B74E0912-E17F-4A7D-8C1E-7EFEDF832E9FQ33762496-357550EF-F6E4-4AB1-9243-4EB1F1D44664Q33894448-4DE72F7B-10EA-44BC-BD38-0E3D21D82CABQ33964836-7C91A243-6FD3-4B47-A806-91C0F8629322Q33985577-57F1BB65-B990-41DD-998E-5C496AC667E1Q34002149-71DC2FF8-6B40-4E59-8ACD-1DC388609917Q34075013-254DE6DC-29FD-4977-8ED2-3381269C4280Q34191650-8F02207B-F1A8-483B-926F-F58C11D11387Q34576367-0D376420-E1FD-4542-8295-D7AF342F4E0BQ34726594-79C8C3CC-BF2B-47EA-839B-9003CA60BCDBQ34805783-FA03A7CE-F77B-4F64-A057-FAEEBE952B32Q34958987-BF10471E-96FC-43D6-B32E-FF12E2832487Q34996675-8881A970-4C03-4F21-8BB7-4E36A8D79F59Q35063753-DDA850E9-7FD4-4F75-A896-F8128DF83487Q35134984-7BD40973-F8EB-4210-943C-164B612609BBQ35176837-6C36E4AF-FE8C-4C15-8D7F-9F40AED8AAA9Q35597214-1925E1F4-F63D-405C-8B23-7D62E9C1B7F1Q35603378-A9F3CF34-3927-4EB9-8AE0-5304921ADD67Q35662667-5B1D0B05-1F50-4E65-87CA-0AE2C16A057DQ35679807-4E099706-CE9E-42EB-88BC-77DB1971632FQ35760732-7FEA7B05-4D83-491A-8512-22A93055EA17Q35763338-25FA5E00-030E-4838-834A-1CEA76A3EDABQ35784481-D81DA2CC-F1DE-4BC2-9C03-0E7E887FA23EQ35870416-006FCE1E-2A45-4104-8BDA-734228DB5549Q35885655-042F9FB5-714B-454A-AA14-B4D547D7F71CQ35925032-402F35E7-53FD-4CE0-8C2B-8A8F39055522
P2860
Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@ast
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en-gb
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@nl
type
label
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@ast
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en-gb
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@nl
prefLabel
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@ast
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en-gb
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@nl
P2093
P356
P1476
Two RGD-independent alpha vbet ...... distinct anti-tumor properties
@en
P2093
P C Colorado
Y Maeshima
P304
P356
10.1074/JBC.C000186200
P407
P577
2000-08-04T00:00:00Z